Why did LendingTree CEO die suddenly?
How will JPMorgan’s $1.5 trillion plan impact US industries?
What caused Broadcom’s stock surge after AI chip deal?
Why did China sanction South Korean shipbuilder subsidiaries?
How will new US-China port fees affect trade?
Why are retailers cutting holiday hiring amid tariffs?
What’s behind Samsung’s profit rebound this quarter?
Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression
benzinga.com/analyst-stock-ratings/initiation/25/10/48185009/mind-medicine-analyst-cites-strong-phase-3-pipeline-anxiety-depression
Needham initiated coverage on Mind Medicine Inc. (NASDAQ:MNMD), or MindMed, on Monday. The late-stage clinical biopharmaceutical company is developing novel product candidates to treat brain health disorders.
The company’s lead drug candidate, MM120 ODT (lysergide D-tartrate or LSD), is a…
This story appeared on benzinga.com, 2025-10-13 18:54:39.